Testing Oncolytic Myxoma Virus in Immunocompetent Mouse Model for Cancer Therapy

Yasmin Shakiba; Masmudur M Rahman

doi:10.1007/978-1-0716-4160-6_22

Testing Oncolytic Myxoma Virus in Immunocompetent Mouse Model for Cancer Therapy

Methods Mol Biol. 2025:2860:353-360. doi: 10.1007/978-1-0716-4160-6_22.

Authors

Yasmin Shakiba¹, Masmudur M Rahman^{2

3}

Affiliations

¹ School of Medical and Biological Physics, Moscow Institute of Physics and Technology, Moscow, Russia.
² Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA. masmudur.rahman@asu.edu.
³ School of Life Sciences, Arizona State University, Tempe, AZ, USA. masmudur.rahman@asu.edu.

PMID: 39621278
DOI: 10.1007/978-1-0716-4160-6_22

Abstract

Oncolytic viruses (OVs) have emerged as a class of novel cancer immunotherapeutic. Members of both DNA and RNA viruses developed as OVs for treating diverse types of human cancers. Preclinical research assessing immunotherapeutic efficacy is an essential step toward further development of these OVs. Mice tumor model systems are widely used in preclinical oncolytic viral therapies for evaluating the treatment regimens' efficacy. However, choosing the most appropriate model for a study can be challenging. Here, we describe a simple method of establishing subcutaneous tumors in immunocompetent mice, intratumoral injection of the virus, measuring tumor burden, and studying the survival of mice for preclinical development of oncolytic myxoma virus (MYXV).

Keywords: B16F10; Cancer cells; Myxoma virus; Oncolytic virotherapy; Oncolytic virus; Preclinical mouse model.

MeSH terms

Animals
Cell Line, Tumor
Disease Models, Animal*
Female
Humans
Immunocompetence
Mice
Myxoma virus* / genetics
Neoplasms / immunology
Neoplasms / therapy
Oncolytic Virotherapy* / methods
Oncolytic Viruses* / genetics
Oncolytic Viruses* / physiology
Tumor Burden